Adenovirus-specific T cell therapy - Cell Medica

Drug Profile

Adenovirus-specific T cell therapy - Cell Medica

Alternative Names: ADV-specific T cell therapy - Cell Medica; Cytovir ADV

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Medica
  • Class Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adenovirus infections

Most Recent Events

  • 03 Feb 2016 Phase-I/II development is ongoing in United Kingdom
  • 08 Jan 2014 The EMA's Committee for Orphan Medicinal Products recommends orphan drug designation for Cytovir™ ADV for Adenovirus infections in immunosuppressed patients following bone marrow transplantation
  • 08 May 2013 Phase-I/II clinical trials in Adenovirus infections in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top